Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nomacopan - Akari Therapeutics

Drug Profile

Nomacopan - Akari Therapeutics

Alternative Names: Coversin; EV 576; long-acting PAS-nomacopan; PAS-coversin; PAS-nomacopan; rEV 576; rVA576

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec; US Army Institute of Surgical Research
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Guillain-Barre syndrome; Bullous pemphigoid; Thrombotic microangiopathies
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome
  • Phase I/II COVID-19 pneumonia; Keratoconjunctivitis
  • Preclinical Asthma; Dry age-related macular degeneration; Haemorrhagic shock; Subarachnoid haemorrhage; Traumatic brain injuries
  • Suspended Thrombotic microangiopathy
  • No development reported Guillain-Barre syndrome; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Uveitis; Wet age-related macular degeneration
  • Discontinued Autoimmune disorders; Bullous pemphigoid; Inflammation; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in United Kingdom (Intravitreous)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Uveitis in United Kingdom (Intravitreous)
  • 19 Aug 2024 Nomacopan - Akari Therapeutics is available for licensing as of 19 Aug 2024. www.akaritx.com 9423868

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top